[1] ZHOU Y,XU X,DING J,et al.Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma［J］.J Cancer Res Ther，2018,14(1):40.
[2]FLORIDI C,BERNARDI ID,FONTANA F,et al.Microwave ablation of renal tumors:state of the art and development trends［J］.Radiol Med，2014,119(7):533-540.
[3]PLANCHE O,TERIITEHAU C,BOUDABOUS S,et al.In vivo evaluation of lung microwave ablation in a porcine tumor mimic model［J］.Cardiovasc Intervent Radiol，2013,36(1):221-228.
[4]CARRAFIELLO G,IERARDI AM,FONTANA F,et al.Microwave vivo evaluation of lung microwave ablation in a porcine tumor mimic model［J］.J Vasc Interv Radiol，2013,24(10):1513-1520.
[5]ZHE Y,JIE G,MINGHUA Z,et al.Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death［J］.Oncotarget，2014,5(15):6526-6539.
[6]ZHU J,YU M,CHEN L,et al.Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer:A pre-clinical study in a murine model ［J］.Diagn Interv Imaging，2018,99(3):S2211568417303418.
[7] BACKLUND M,FREEDMAN JJCRIO.Microwaveablation and immune activation in the treatment of recurrent colorectal lung metastases:a case report［J］.Case Rep Oncol，2017,10(1):383-387.
[8]YANG X,YE X,ZHANG L,et al.Microwave ablation for lung cancer patients with a single lung:Clinical evaluation of 11 cases［J］.Thorac Cancer，2018,9(5):548.
[9] YUANYUAN S,YANG W,XIAOXIA N,et al.Comparison of ablation zone between 915-and 2,450-MHz cooled-shaft microwave antenna:results in in vivo porcine livers［J］.AJR Am J Roentgenol,2009,192(2):511-514.
[10]XU Y,SHEN Q,WANG N,et al.Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma［J］.Chin J Cancer,2017,36(5):14.
[11]YOUNG-SUN K,HYO KEUN L,HYUNCHUL R,et al.Ablation of hepatocellular carcinoma［J］.World J Hepatol，2014,72(1):124-131.
[12]MEHTA A,OKLU R,SHETH RAJGR,et al.Thermal ablative therapies and immune checkpoint modulation:can locoregional approaches effect a systemic response［J］.Gastroenterol Res Pract，2016,4:9251375.
[13]RANJNA S,WAGNER JL,HWANG RF.Surgical oncology clinics of north America.ablative therapies of the breast［J］.Surg Oncol Clin N Am,2011,20(2):317-339.
[14]PENG Y,CUI D,LI W,et al.Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe:A pilot clinical study［J］.J Cancer Res Ther,2021,17(3):764-770.
[15]CHARGIN A,MORGAN R,SUNDRAM U,et al.Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer(NSCLC)using non-enzymatic tissue dissociation and flow cytometry［J］.Cancer Immunol Immunother,2016,76(14):1372.
[16] GUISLAIN A,GADIOT J,KAISER A,et al.Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma［J］.Cancer Immunol Immunother,2015,64(10):1241-1250.
[17]LINARDOU H,GOGAS HJAOTM.Toxicity management of immunotherapy for patients with metastatic melanoma［J］.Ann Transl Med,2016,4(14):272.
[18] KEI S,KYUICHI K,SIMA CS,et al.Clinical impact of immune microenvironment in stage I lung adenocarcinoma:tumor interleukin-12 receptor β2(IL-12Rβ2),IL-7R,and stromal FoxP3/CD3 ratio are independent predictors of recurrence ［J］.Clin Oncol,2013,31(4):490-498.
[19] TAKAHASHI Y,HORIO H,TAI H,et al.Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage Ⅰ non-small cell lung cancer after complete resection ［J］.Ann Surg Oncol,2015,22(3):1324-1331.
[20]TAKAHASHI Y,KAWAMURA M,TAI H,et al.Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection［J］.World J Surg,2016,40(2):365.
[21]WEIDE B,ALLGAIER N,HECTOR A,et al.Increased CCL17 serum levels are associated with improved survival in advanced melanoma ［J］.Cancer Immunol Immunother,2015,64(9):1075-1082.
[22] FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial［J］.Lancet,2016,387(10030):1837-1846.
[23]ASCIERTO PAJCII.Immunotherapies and novel combinations:the focus of advances in the treatment of melanoma［J］.N Engl J Med,2015,64(3):271-274.
[24]QI Q,GENG Y,SUN M,et al.Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer［J］.Pancreatology,2015,15(2):145-150.
[25]HOSSEIN B,LUIS PA,LEORA H,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.N Engl J Med,2015,373(17):123-135.
[26]MOTZER RJ,BERNARD E,MCDERMOTT DF,et al.Nivolumab versus everolimus in advanced renal-cell carcinoma［J］.Lancet Oncol,2016,17(7):917-927.
[27]WEBER JS,D'ANGELO SP,DAVID M,et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment(CheckMate 037):a randomised,controlled,open-label,phase 3 trial［J］.Lancet Oncol,2015,16(4):375-384.
[28]SHI L,CHEN L,WU C,et al.PD-1 Blockadeboosts radiofrequency ablation-elicited adaptive immune responses against tumor［J］.Clin Cancer Res,2016,22(5):1173.
[29]EI-KHOUEIRY AB,SANGRO B,YAU T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trail［J］.Lancet,2017,389(10088):2492.
[30]LOPES G,WU YL,KUDABA I,et al.Pembrolizumab(pembro)versus platinum-based chemotherapy(chemo)as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score(TPS)≥1%:Open label,phase 3 KEYNOTE-042 study［J］.J Clin Oncol,2018,36(18):2.
[31]LI G,STAVELEY-O'CARROLL KF,KIMCHI ET.Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma ［J］.J Clin Trials,2016,6(2):257.
[32]苗同国，王立静，马立伟，等.射频消融治疗对原发性肝癌患者T细胞免疫功能的影响［J］.中国微创外科杂志,2016,16(6):538-540.
MIAO TG,WANG LJ,MA LW,et al.Effects of radiofrequency ablation on t-cell immune function in patients with primary liver cancer［J］.Chinese Journal of Minimally Invasive Surgery,2016,16(6):538-540.
[33]刘江伟,黄建钊,孙倩,等.射频消融术对原发性肝癌患者外周血淋巴细胞亚群的影响［J］ 中国普外基础与临床杂志，2015,22(10):1171-1174.
LIU JW,HUANG JZ,SUN Q,et al.Effect of radiofrequency ablation on peripheral blood lymphocyte subsets in patients with primary liver cancer［J］.Chinese Journal of Bases and Clinics in General Surgery，2015,22(10):1171-1174.
[34]ZHANG H,HOU X,CAI H,et al.Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma［J］.Minim Invasive Ther Allied Technol,2017,26(4):207-211.
[35]MO Z,LU H,MO S,et al.Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer［J］.Oncol Lett,2018,15(5):7014-7020.
[36]ZHANG KQ,ZHANG JRJNFYKDXXB.Therapeutic effects of cryoablation,radiorequency ablation,and microwave coagulation against VX2 liver cancera comparative study in rabbits［J］.
Journal of Southern Medical University,2007,27(9):1431-1434.
[37]DUAN X,WANG M,HAN X,et al.Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice［J］.Cell Cycle,2020,19(24):3595-3607.
[38]WEI Z,YANG X,YE X,et al.Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer［J］.J Cancer Res Ther,2019,15(7):1629-1634.
[39]LEMDANI K,MIGNET N,BOUDY V,et al.Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma［J］.Oncoimmunology,2019,8(3):1550342.
[40]KOELZER VH,LUGLI A,DAWSON H,et al.CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival［J］.Transl Med,2014,12(1):81.
[41]SELBY MJ,ENGELHARDT JJ,QUIGLEY M,et al.Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells［J］.Cancer Immunology Research,2013,1(1):32-42.
[42]DUFFY AG,ULAHANNAN SV,MAKOROVA-RUSHER O,et al.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma［J］.J Hepatol,2017,66(3):545-551.
[43]KUDO MJO.Immuno-oncology in hepatocellular carcinoma:2017 update［J］.Oncology,2017,93(1):147.
[44]RAUFI A,TIRONA MTJCMR.Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments ［J］.Cancer Manag Res,2017,9(9):19-27.
[45]LIU H,SHEN J,LU KJB,et al.IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model［J］.Biochem Biophys Res Commun,2017,486(2):239-244.
[46]WANG Q,WU XJII.Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment［J］.Int Immunopharmacol,2017,46:210-219.